May 15–16, 2019 Boston Convention & Exhibition Center Boston, MA

PLASTEC New England 2017 Schedule Viewer

Use the scheduling tool below to browse all the available sessions, speakers, and topics at this year's event. Find the content and sessions to fit all of your educational needs and ensure you get the most out of your time at the event.
All SessionsSpeakersMy Schedule
View Sessions As:
  • Edward Damiano, PhDChief Executive OfficerBeta Bionics

    Edward Damiano is a Professor of Biomedical Engineering at Boston University and President and CEO of Beta Bionic, Inc., a Massachusetts public benefit corporation. His expertise and training are in the areas of mechanical and biomedical engineering, applied mechanics, and applied mathematics. His basic scientific research has combined fluid dynamics with intravital microscopy to study blood flow in the microcirculation and to elucidate mechanisms by which the lining of blood vessels determines vascular health and disease. In particular, his lab has focused on the endothelial glycocalyx, which consists of a complex mucopolysaccharide and macromolecular assembly that is situated at the interface between the luminal vascular wall and flowing blood. Beyond his basic science research is his interest in translational research.
    Ever since his 17-year-old son, David, developed type 1 diabetes (T1D) as an infant, he has been committed to creating and integrating blood-glucose control technologies with a vision of building a dual-hormonal (insulin and glucagon) bionic pancreas that his son could take to college. This work began over a dozen years ago with the design and development of mathematical dosing algorithms for blood-glucose control. He and his group ran those dosing algorithms on a laptop computer back then, and began testing them in experiments in diabetic swine in 2005. Working with his clinical collaborators at the Massachusetts General Hospital, they progressed through in-patient clinical trials in adults and adolescents with T1D from 2008–2012. From 2013–2016, his team at BU and his clinical collaborators conducted six outpatient clinical trials in adults and children 6 years and older with T1D testing a mobile version of their bionic pancreas, which integrated an iPhone with their mathematical dosing algorithms, two infusion pumps, and a continuous glucose monitor. With $2.5MM in donations from over 1,000 gifts from the T1D community, his engineering team, along with their industrial collaborators in the medical device industry, built a prototype system in 2014 and 2015 of their first fully integrated biohormonal bionic pancreas that does not rely upon smartphone technology. They call their device the iLet, in homage to the pancreatic islets of Langerhans. They recently received FDA approval to begin clinical trials testing the iLet in the outpatient setting. His goal is to begin the final pivotal trials testing their commercial version of the iLet in 2017.